GlassScriptPhysician profile
Kevin J Gilbert
NPI 1871558742
$3,571.87
in general payments reported to CMS, 2019-2025
28 companies · $391 in 2025
The $391 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $531 · 2020: $633 · 2021: $717 · 2022: $515 · 2023: $313 · 2024: $473 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,176.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $798.19 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $407.53 | 2019-2025 | Cardiomems, Freestyle Libre 3, Eterna |
| Abbvie INC. | $338.24 | 2021-2023 | |
| Novo Nordisk INC | $329.49 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $274.81 | 2020-2025 | Airsupra |
| Glaxosmithkline, LLC. | $224.75 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $174.40 | 2019-2022 | |
| Amarin Pharma, INC. | $174.11 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $122.70 | 2019 | |
| Allergan, INC. | $110.55 | 2020 | |
| Sanofi-Aventis U.S. LLC | $104.58 | 2019-2022 | |
| Amgen INC. | $70.96 | 2022-2024 | Repatha |
| Exact Sciences Corporation | $69.92 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $42.85 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $42.69 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $38.77 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.46 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.64 | 2022 | |
| Lundbeck LLC | $24.83 | 2024 | Rexulti |
| Antares Pharma, INC. | $21.93 | 2019 | |
| Idorsia Pharmaceuticals US INC | $21.45 | 2023 | Quviviq |
| Almatica Pharma LLC | $21.27 | 2023 | Gralise, Loreev Xr, Sertraline Hcl |
| Amneal Pharmaceuticals LLC | $20.70 | 2022 | |
| Gilead Sciences, INC. | $18.10 | 2025 | |
| Tolmar, INC. | $16.52 | 2025 | Jatenzo |
| Phathom Pharmaceuticals, INC. | $16.20 | 2024 | Voquezna |
| Dexcom, INC. | $15.99 | 2024 | Dexcom G6 Transmitter |
| Arbor Pharmaceuticals, INC. | $12.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Gilbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.